ClinicalTrials.gg
TerminatedNCT04500678Updated Oct 20, 2026Results posted

Impact of Metformin on Immuno-virologic Parameters in HIV

A Phase 2/3 interventional study of Metformin in HIV/AIDS, sponsored by University of Hawaii. Terminated at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Hawaii · Phase 2/3, Interventional, and Diagnostic

How we know

Why this study was terminated
During the COVID pandemic, our IRB halted enrollment into the study among other changes. Post COVID it was decided that too long an interval between patient enrollment was problematic for the study and a discussion was made to terminate.

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Feb 2019, registered Jul 2020).
Updated Oct 20, 2026Now TerminatedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States — 112 open to participants now, 154 under way, 9 of them phase 3. Acquired Immunodeficiency Syndrome · United States.

Enrollment
950th of 1,291
29 · median 60
Started
2019
with 76 others
Phase 2/3
18 of 1,671
2 open now
Registered
1,433rd of 1,671
by date

Among the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, this one is the 950th largest by enrollment of the 1,291 interventional ones that give a count, is one of 77 that started in 2019, is one of 18 in phase 2/3, and was the 1,433rd registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

112 of the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, or all of them as a file.
02

Study summary

Non-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized to metformin therapy or to observation for 72 weeks. Primary objective is to assess change over 72 weeks in CD4 T cell negative checkpoint receptors (PD-1 and TIGIT). The study will also explore the 72 week impact of metformin on change in carotid intima-media thickness (cIMT) as a surrogate marker of atherosclerosis, on neuropsychological (NP) performance, strength, and change in body composition.

03

Conditions studied

  • HIV/AIDS

Keywords

  • HIV
  • metformin
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • +
  • On suppressive ART stable for > 1 year
  • Plasma HIV RNA \< 50 copies/mL within 3 months of entry, with no HIV RNA > 200 copies/mL within the past 6 months prior to entry
  • Age >40 years
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled chronic medical condition or cancer
  • Acute illness within 2 weeks of entry
  • Diagnosis of diabetes by history, fasting blood glucose >126, or by HgbA1c > 6.5
  • Chronic, uncontrolled diarrhea
  • Known or to metformin use
  • Current presence of including currently on or intent to start therapy for hepatitis C within the 48 week duration of study.
  • Serum B12 level below the reference normal range as listed by the commercial lab utilized for this study (Diagnostic Laboratory Services)
  • Pregnancy, or intent to become pregnant or nursing an infant
  • Any immunomodulator, vaccine, any other vaccine, or therapy within 30 days of study entry.
  • Current uncontrolled coronary artery disease or Class 3 or 4 congestive heart failure
  • History of liver cirrhosis
  • Current use of zidovudine, stavudine or didanosine
  • The following lab values

    • \< 9.0 g/dL
    • \< 1000/μL
    • count \< 50,000/μL
    • (SGOT) and ALT (SGPT) > 5x (ULN)
    • Calculated (Cockcroft and Gault) \< 50 ml/min
  • Active or recent past history (within past 2 years) of illicit substance or alcohol use or abuse which, in the judgment of the Investigator, will interfere with the patient's ability to comply with the protocol requirements
  • Patients, who, in the opinion of the Investigator, are unable to comply with the dosing schedule and protocol evaluation or for whom the study may not be advisable
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Metformin

    Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.

    Drug: Metformin

  • No intervention
    Observation

    Observed without metformin

Interventions

  • Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.

06

What researchers measure

Primary outcomes

  1. Change in Percentage of CD4 T Cells Expressing PD1+TIGIT+

    Percentage of CD4 T cells co-expressing PD-1 and TIGIT. Change calculated as Week 72 minus Entry; negative values indicate a decrease.

    Time frame: Entry to week 72

07

Results

Posted Oct 20, 2026
Limitations and caveats
The study was halted due to the impact of the COVID pandemic. The total number of evaluable participants was very small limiting our ability to analyze. Also, while participants already on the study continued to be followed during the pandemic, immunologic changes due to COVID may also have interfered with the results of the primary analysis.

Participant flow

Participant flow — Overall Study
MilestoneMetforminObservation
Started1415
Completed711
Not completed74

Outcome measures

PrimaryChange in Percentage of CD4 T Cells Expressing PD1+TIGIT+

Percentage of CD4 T cells co-expressing PD-1 and TIGIT. Change calculated as Week 72 minus Entry; negative values indicate a decrease.

Time frame:
Entry to week 72
Reported as:
Mean · Percentage of PD-1+TIGIT+ CD4 T cells
Change in Percentage of CD4 T Cells Expressing PD1+TIGIT+
Percentage of PD-1+TIGIT+ CD4 T cellsMetforminObservation
Change in Percentage of CD4 T Cells Expressing PD1+TIGIT+-0.787 ± 1.372-1.466 ± 1.713
Statistical analysis
  • Metformin vs Observation · Wilcoxon (Mann-Whitney) · p = 0.8125

Adverse events

Collected over from enrollment until end of follow-up, up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin0/14 (0%)0/14 (0%)4/14 (28.6%)
Observation0/15 (0%)0/15 (0%)1/15 (6.7%)
Most frequent other events
Most frequent other events
EventMetforminObservation
Gastrointestinal SymptomsGastrointestinal disorders4/141/15

Baseline characteristics

the number of participants is smaller as only those participants who completed the study to week 72 were analyzed

Age, Continuous
Age, Continuous(years)MetforminObservationTotal
Mean59.6 ± 9.19560.64 ± 8.48260.1 ± 8.715
Sex: Female, Male
Sex: Female, Male(Participants)MetforminObservationTotal
Female011
Male141428
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MetforminObservationTotal
Hispanic or Latino011
Not Hispanic or Latino141428
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MetforminObservationTotal
White11617
Black101
Asian022
Other/More than One Race279
PD-1+TIGIT+ CD4 cells
PD-1+TIGIT+ CD4 cells(percentage of PD-1+TIGIT+ CD4 cells)MetforminObservationTotal
Mean11.13 ± 4.289.49 ± 3.8510.49 ± 4.09
08

Study locations

1 site
  • John A. Burns School of Medicine, University of Hawaii - Manoa
    Honolulu, Hawaii 96813, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Dataset will be available to other researchers upon request once the primary manuscript is written

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After the study analyses are completed and primary manuscript is published, and for a duration of at least 5 years afterwards

Access criteria: De-identified dataset will be provided upon request to legitimate researchers

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Feb 2022, 36 months.

Results were first posted in Oct 2026, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2020
First posted
Aug 5, 2020
StartActual
Feb 1, 2019
Primary completionActual
Feb 1, 2022
CompletionActual
Dec 31, 2022
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated During the COVID pandemic, our IRB halted enrollment into the study among other changes. Post COVID it was decided that too long an interval between patient enrollment was problematic for the study and a discussion was made to terminate.
changed Oct 20, 2026
Results
Results posted
posted Oct 20, 2026
Enrollment
38 (estimated)→29 (actual)
Oct 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Percentage of CD4 T cellCells Expressing PD1+TIGIT+Time frame: Entry to week 72
Oct 20, 2026
Documents
Secondary outcomes
12 removed
What changed in the outcomes
  • RemovedCD8 T cell PD1+TIGIT+Time frame: Entry to week 72
  • RemovedPlasma levels of indoleamine 2,3-dioxygenase (IDO)Time frame: Entry to week 72
  • RemovedPeripheral blood CD4 T cell intracellular HIV DNATime frame: Entry to week 72
  • RemovedPeripheral blood CD4 T cell intracellular HIV RNATime frame: Entry to week 72
  • RemovedPeripheral blood monocyte intracellular HIV DNATime frame: Entry to week 72
  • RemovedPeripheral blood monocyte intracellular HIV RNATime frame: Entry to week 72
  • Removedother outcomeSafety and Tolerability: # of grade 2 or greater adverse events in each armTime frame: Entry to week 72
  • Removedother outcomeCarotid intima-media thicknessTime frame: Entry to week 72
  • Removedother outcomeNeuropsychological testing global Z scoreTime frame: Entry to week 72
  • Removedother outcomeBeck's Depression Index II scoreTime frame: Entry to week 72
  • Removedother outcomeHandgripTime frame: Entry to week 72
  • Removedother outcomeTotal lean tissue by dual energy absorptiometry (DXA)Time frame: Entry to week 72
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Status unknown→Terminated
    Why stopped During the COVID pandemic, our IRB halted enrollment into the study among other changes. Post COVID it was decided that too long an interval between patient enrollment was problematic for the study and a discussion was made to terminate.
    Results posted
    Enrollment 38 (estimated)→29 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Percentage of CD4 T cellCells Expressing PD1+TIGIT+Time frame: Entry to week 72
    Secondary outcomes 12 removed
    What changed in the outcomes
    • RemovedCD8 T cell PD1+TIGIT+Time frame: Entry to week 72
    • RemovedPlasma levels of indoleamine 2,3-dioxygenase (IDO)Time frame: Entry to week 72
    • RemovedPeripheral blood CD4 T cell intracellular HIV DNATime frame: Entry to week 72
    • RemovedPeripheral blood CD4 T cell intracellular HIV RNATime frame: Entry to week 72
    • RemovedPeripheral blood monocyte intracellular HIV DNATime frame: Entry to week 72
    • RemovedPeripheral blood monocyte intracellular HIV RNATime frame: Entry to week 72
    • Removedother outcomeSafety and Tolerability: # of grade 2 or greater adverse events in each armTime frame: Entry to week 72
    • Removedother outcomeCarotid intima-media thicknessTime frame: Entry to week 72
    • Removedother outcomeNeuropsychological testing global Z scoreTime frame: Entry to week 72
    • Removedother outcomeBeck's Depression Index II scoreTime frame: Entry to week 72
    • Removedother outcomeHandgripTime frame: Entry to week 72
    • Removedother outcomeTotal lean tissue by dual energy absorptiometry (DXA)Time frame: Entry to week 72
    + 8 other changes: index terms, verification date, date precision, responsible party, description, conditions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04500678
Lead sponsor
University of Hawaii
Responsible party
Cecilia M Shikuma (Professor, Medicine, University of Hawaii) — Principal investigator
First posted
Aug 5, 2020
Start date
Feb 1, 2019
Primary completion
Feb 1, 2022
Completion
Dec 31, 2022
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Cecilia M Shikuma, MD
principal investigator · University of Hawaii

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion